Clinical Report: Correction on Cadonilimab in Pancreatic Cystadenocarcinoma

Overview

Revise to include direct attribution to the source regarding the correction of authorship.

Background

Remove unsupported claims about innovative therapeutic approaches and the role of cadonilimab.

Data Highlights

No numerical or trial data is provided in the correction article.

Key Findings

• Correction acknowledges Jiaju Xu as an equal contributing author.
• Cadonilimab is being studied for its potential in treating microsatellite-stable pancreatic cystadenocarcinoma.
• Immunotherapy is generally not recommended for microsatellite-stable pancreatic cancer according to current guidelines.
• Checkpoint blockade therapies have shown limited efficacy in pancreatic cancer due to low prevalence of MSI-H/dMMR.
• Emerging data suggest cadonilimab may have specific signals in pancreatic ductal adenocarcinoma.

Clinical Implications

The correction of authorship highlights the collaborative nature of research in oncology. Clinicians should remain informed about ongoing studies involving cadonilimab and its potential role in treating pancreatic cancer, particularly in the context of evolving immunotherapy strategies.

Conclusion

The correction serves to accurately represent contributions to the research on cadonilimab, emphasizing the importance of collaboration in advancing treatment options for pancreatic cancer.

Related Resources & Content

1. Ni C, Xu J, Pang Y, Xu J, Front. Immunol, 2026 -- Correction on Converting an immunologically “cold” tumor
2. The ASCO Post — Preclinical Study Examines Novel Pancreatic Cancer Treatment
3. The ASCO Post — Triple Immunotherapy Combination Studied Preclinically for Pancreatic Cancer
4. The ASCO Post — Scientists Are Boosting Immune Responses in Pancreatic Tumors
5. ADA News — Study Finds Immune Enrichment Improves Outcomes in Pancreatic Cancer With Activated but Not Normal Stroma
6. Preclinical Study Examines Novel Pancreatic Cancer Treatment
7. Triple Immunotherapy Combination Studied Preclinically for Pancreatic Cancer
8. Scientists Are Boosting Immune Responses in Pancreatic Tumors
9. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer
10. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab
11. Pancreatic Cancer - Oncology - Merck Manual Professional Edition